Management Forum Logo

Presented by
Management Forum

Drafting Effective Pharmaceutical Patents Training Course

Drafting successful pharmaceutical patents is complex and there are many pitfalls and risks to be aware of. You need to ensure you’re maximising the protection for your, and your client’s, pharmaceutical inventions thorough both primary and secondary pharmaceutical patents.

1-4 Nov 2022 + 2 more dates

Need help?  Enrol or reserve

  • Format: Live online
  • CPD: 12 hours for your records
  • Certificate of completion

Course overview

The highly complex area of pharmaceutical patents is looked at in detail in this course. The expert faculty will take you through the key differences between the European and US systems and how these can impact your patents. They will explore the latest strategies and give you useful insights and practical solutions to your drafting issues. By understanding the importance of aligning your patent and regulatory strategies, you will improve your pharmaceutical claim drafting skills to the best advantage.

The practical claim drafting exercises included in the course will give you an opportunity to get to grips with the information in a safe environment and under the guidance of the trainers. They will help embed what you have learnt so that it can be taken back to the workplace and put into practice. As well as receiving inside knowledge and top tips and advice from the highly experienced professionals from industry and private practice, the course also provides a valuable opportunity to network with others in similar roles from different companies. By attending, you can discuss your challenges with colleagues and our expert faculty and find solutions to your questions.

Key topics covered in this intensive training programme include:

  • Drafting primary patents and secondary patents
  • Key differences between drafting for Europe versus the US
  • Claim drafting strategies for antibodies and other biologics
  • Drafting claims that ‘follow the label’
  • Drafting patent applications with sufficient supporting data – how much is enough?
  • Aligning your patent strategy with regulatory issues

Who should attend?

  • Patent attorneys
  • In-house lawyers
  • Private practice lawyers
  • Patent agents and consultants

Enrol or reserve

The Drafting Effective Pharmaceutical Patents course will cover:

Summary of the course

  • Overview of the programme
  • Patentability basics

Drafting primary patents – small molecules

  • Protecting pharmaceutical compositions
  • Protecting methods of treatment
  • Protecting medical use claims (first, second and Swiss-type)

Drafting primary patents – biologics

  • Drafting sequence disclosures
  • Protecting antibodies, stem cells and microorganisms
  • Drafting generic and species claims
  • Drafting functional claim language
  • Protecting gene therapy inventions

Primary patents workshop

  • Selection inventions
  • Drafting claims for infringement
    • Distilling down the invention disclosure
    • Patenting later developments
  • Practical examples and drafting exercises

Drafting with a focus towards interplay with regulatory issues

  • Patent term extension and SPCs
  • Regulatory issues and data protection – drafting to ‘follow the label’
  • The ANDA litigation process and enforcement of listed patents
  • Overlay of patent protection with FDA exclusivity – the FDA Orange Book
  • Strategies for protecting biologics

Data needed to support patent applications

  • What data must be included?
  • When must the data be included?
  • Consideration of post-filing date data
  • US written description
  • The importance of correct data – avoiding inequitable conduct

Secondary patents

  • Protecting dosage regimes, modes of administration, patient groups
  • Protecting polymorphs (crystals, enantiomers, salts)
  • Protecting metabolites
  • Protecting new formulations
  • Protecting process patents
  • Protecting methods of diagnosis and surgery

Secondary patents workshop

  • Establishing patentability: inventive step vs non-obviousness
  • Strategies for using post-filing evidence
  • Practical examples and drafting exercises

Enrol or reserve

Anthony Tridico

Anthony Tridico is the managing partner of Finnegan’s European office in London, United Kingdom. Dr Tridico has more than 15 years of experience in the field of intellectual property law and his practice involves diverse technical areas from biotechnology, chemical and pharmaceutical sciences to medical devices, diagnostic tools and instrumentation. A significant portion of his current practice is devoted to post-grant proceedings, appeals and oral hearings at the USPTO’s Patent Trial and Appeal Board, as well as European Patent Office (EPO) opposition and appeal procedures. Dr Tridico also focuses on international patent prosecution and portfolio management as well as strategic counselling including pre-litigation analysis, due diligence investigations, and the specialized areas of patent term extensions and Orange Book listings.

Working in Europe for much of his career, Dr Tridico has gained significant knowledge of the European Patent Convention (EPC) and the diversity of laws and practice among the European national systems. His knowledge of the European legal system and how it differs from the United States allows Dr Tridico to effectively counsel clients with global interests in intellectual property. He has also successfully represented clients in U.S. district court and multi-national patent litigations including protecting the rights of innovative pharmaceutical companies in Abbreviated New Drug Application (ANDA) litigations.

Dr Tridico is a frequent lecturer on intellectual property issues at various international programs and conferences targeted to the U.S. and European business community. He has spoken before numerous Fortune 500 companies and multi-national organizations throughout the world. 


BTG Int’l Ltd. v. Kappos (E.D. Va.). Represented BTG International Ltd. in the first post-AIA 35 U.S.C. § 145 action in the District Court for the E.D. Va. on an appeal from the USPTO regarding a patent application directed to CDw52 specific antibodies.

Represents Pronova BioPharma in Hatch-Waxman litigations against two companies seeking FDA approval to market generic versions of Lovaza® which had 2011 sales of over $900 million. The district court found the asserted patent claims valid, enforceable and infringed in May 2012, thus precluding marketing of any generics until April 2017.

Professional Activities

American Intellectual Property Law Association

American Chemical Society

Sigma Xi

Select Publications

Coauthor. “Spring Update: More Lessons Learned from the New Post-Grant Proceedings,” CIPA Journal, March 2014.

Coauthor. “Novartis v. Lee: A New Method for Calculating U.S. Patent Term Adjustment,” CIPA Journal, Feb. 2014.

Coauthor. “IP5 PPH Pilot Program,” Intellectual Property Today, Jan. 2014.

More details

Amanda Murphy

Dr. Amanda Murphy is a Partner in Finnegan’s Washington, DC Office and focuses her practice on strategic client counseling, portfolio management, and patent prosecution for a range of clients, including small startup companies, research foundations, and large biotechnology and pharmaceutical companies.
Amanda provides patentability opinions, prepares new patent applications, prosecutes U.S. and foreign applications, and represents appellants before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). She has experience in prosecuting inter partes and ex parte reexamination applications, reissue applications, and patent term extension applications for approved pharmaceuticals, including obtaining supplemental protection certificates in Europe. In addition to her patent counseling and prosecution practice, Amanda also routinely represents petitioners and patent owners in inter partes review (IPR) and post grant review (PGR) proceedings before the PTAB. As part of that practice, Amanda works with experts to develop technical and legal bases for challenging or defending issued patents, and manages the preparation of substantive written submissions. She also provides strategic advice and pre-litigation analysis and prepares freedom-to-operate, enforceability, and infringement opinions.

More details

Anthony Tridico

Dr. Anthony Tridico is the Managing Partner of Finnegan’s European office in London and has over 20 years of experience protecting pharmaceutical inventions. Anthony practices all aspects of intellectual property law, from strategic patent portfolio management to litigation including strategic client counselling, due diligence investigations, patent portfolio management and analysis, prosecution and drafting, and appeals and oral hearings at the Patent Trial and Appeal Board (PTAB). He also offers expertise in representing clients in the specialised areas of FDA Orange Book listing of patents, and patent term extensions. Anthony has served for over 15 years as adjunct professor at Georgetown University Law School teaching patent law and patent prosecution and he has been recognized by Intellectual Asset Management as a leading patent prosecutor in the United Kingdom and Europe in the IAM Patent 1000, and as a top IP strategist by the IAM Strategy 300. Managing Intellectual Property named him an “IP Star” in the United Kingdom.

More details

Book Drafting Effective Pharmaceutical Patents Live online training

NEW higher discounts for multiple bookings - bring your colleagues to make your training budget go further:

  • 30% off the 2nd delegate*
  • 40% off the 3rd delegate*
  • 50% off the 4th delegate*

Please contact us for pricing if you are interested in booking 5 or more delegates

1-4 Nov 2022

Live online

13:30-17:00 UK (London) (UTC+00)
14:30-18:00 Paris (UTC+01)
09:30-13:00 New York (UTC-04)
Course code 11882

  • GBP 899 1,099
  • EUR 1,299 1,579
  • USD 1,474 1,786

Until 27 Sep

View basket 

Not ready to book yet?

for 7 days, no obligation

16-19 May 2023

Live online

13:30-17:00 UK (London) (UTC+01)
14:30-18:00 Paris (UTC+02)
08:30-12:00 New York (UTC-04)
Course code 12165

  • GBP 999 1,199
  • EUR 1,439 1,719
  • USD 1,647 1,959

Until 11 Apr

View basket 

Not ready to book yet?

for 7 days, no obligation

6-9 Nov 2023

Live online

13:30-17:00 UK (London) (UTC+00)
14:30-18:00 Paris (UTC+01)
08:30-12:00 New York (UTC-05)
Course code 12398

  • GBP 999 1,199
  • EUR 1,439 1,719
  • USD 1,647 1,959

Until 02 Oct

View basket 

Not ready to book yet?

for 7 days, no obligation

* Early booking discounts may not be combined with other discounts or offers. As such, the discounts for 2nd/3rd/4th delegates are based on the full price.

United Kingdom

  • Adamson Jones
  • CMS Cameron McKenna Nabarro Olswang LLP
  • Croda Europe Limited
  • Forresters
  • Nordic Pharma
  • UCB Celltech Ltd


  • Alk Abello
  • Hoiberg A/S
  • Leo Pharma A/S
  • Novo Nordisk A/S


  • IPR Partners Ltd
  • Kolster OY AB


  • Fundacao Biominas


  • Grunenthal GmbH


  • Chinoin Zrt - member of sanofi-aventis Group


  • Raul Cesar Ferreira (Herd) SA


  • Strom & Gulliksson AB


  • Nestec SA

Enrol or reserve

Run Drafting Effective Pharmaceutical Patents Live online for your team

2 days

Typical duration

Pricing from:

  • GBP 800
  • Per attendee
  • Course tailored to your requirements
  • At your choice of location, or online


We can customise this course to your requirements and deliver it on an in-house basis for any number of your staff or colleagues.

Contact our in-house training expert Aleksandra Beer to discuss your requirements:

Multiple colleagues? See above for details of our discounts for 2, 3, or 4 delegates. For more, talk to one of our training experts to discuss how to:

Run this course conveniently and cost-effectively in-house for your staff and colleagues

Aleksandra BEER
Training expert

+44 (0)20 7749 4749